- Lobbying
- Lobbying by Pardes Biosciences, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
JOHN MARTIN | Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Registration
Issue(s) they said they’d lobby about: Funding for COVID-19 Therapeutics, specifically Oral Antivirals.
Advance Purchase Agreements
Strategic National Stockpile
Pandemic Preparedness.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate